• ≥ 18 years old (for Korean ≥ 19 years old)

• ECOG performance status 0-2 with no deterioration over the previous 2 weeks

• Predicted life expectancy ≥ 12 weeks.

• Histologically confirmed PTCL by local pathology review according to the 2016 revision of the WHO classification of lymphoid neoplasms. Eligible histological subtypes are restricted to the following:

‣ PTCL-NOS

⁃ AITL

⁃ ALCL ALK+

⁃ EATL

⁃ MEITL

⁃ NKTCL

⁃ HSTCL

⁃ SPTCL

• Have measurable disease according to the 2014 Lugano classification

• Must have progressed on or are refractory to standard systemic therapy, or patients were intolerant to standard systemic therapy. Participants should be transplant-ineligible upon their entries to this study.

• Adequate bone marrow reserve and organ system functions

• LVEF ≥ 55% assessed by ECHO or MUGA.

• Male participant with female partners of child-bearing potential should be willing to use barrier contraceptives (i.e., by use of condoms), during his participation in this study and for 6 months following the last dose of the study drug. Male participant must refrain from donating sperm during their participation in the study and at least for 6 months after the last treatment.

⁃ Female participant should be using adequate contraceptive measures while on study drug and for 3 months following the last dose of study drug.